Cost-Effective Insulin Options for Humana Medicare Advantage Patients

Cost Comparison of Insulin Products

Human regular insulin is available at some pharmacies for approximately $25 per vial, making it the most affordable insulin option 2, 3
NPH insulin is also available at similar low prices ($25-35 per vial) and can be used as an intermediate-acting insulin 1, 4
The median National Average Drug Acquisition Cost (NADAC) for human regular insulin is approximately $132 per 1,000 units for standard U-100 vials 1
Insulin glargine follow-on products like Basaglar have a median NADAC of approximately $95 per 1,000 units for vials, making them a more affordable long-acting option 1, 5
Lispro follow-on products have a median NADAC of approximately $94 per 1,000 units for vials, making them a more affordable rapid-acting option 1
Brand-name rapid-acting insulin analogs have median NADACs of $140-277 per 1,000 units 1
Long-acting insulin analogs like detemir and degludec have median NADACs of $296-326 per 1,000 units 1, 5

Human regular insulin has a slower onset and longer duration compared to rapid-acting analogs 6, 4
Human regular insulin requires administration 30 minutes before meals for optimal effect 3
NPH insulin is an intermediate-acting insulin with onset of 1 hour, peak at 6-8 hours, and duration of 12 hours 6, 4
NPH insulin requires consistent meal timing and content due to its peak action profile 6
NPH insulin may have higher risk of nocturnal hypoglycemia compared to long-acting analogs 2

The American Academy of Family Physicians recommends starting with human regular insulin for meal coverage (available for ~$25/vial) 2, 3
The American Academy of Family Physicians suggests adding NPH insulin for basal coverage if needed (also available for ~$25-35/vial) 6, 4
Consider premixed 70/30 formulations if simplification is needed, also available at lower cost 1, 2
Upgrade to insulin glargine follow-on products like Basaglar only if NPH causes problematic hypoglycemia 1, 5

Medicare Part D has implemented a $35 monthly cap on insulin costs, which may affect out-of-pocket expenses regardless of the insulin chosen 1
Patients should be educated about the different onset, peak, and duration profiles of human insulins compared to analogs to ensure safe and effective use 6, 4